PIN Pharma to Present a Poster at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

NEW YORK–(BUSINESS WIRE)– PIN Pharma, a pre-clinical immunotherapy company focused on modulating
the immune system in oncology, today announced the Company will be
presenting PIN-2: A Novel Immunopriming Peptide
with Immunomodulatory Activity Linking the Innate and Adaptive Immune
Systems at Poster Session B on Monday, September 26, 2016 from
5:30 pm – 8:00 pm.

About PIN Pharma, Inc.

PIN Pharma is a pre-clinical stage venture backed immunotherapy company
focused on the development of PINS (precision immune stimulants). The
lead compound PIN-2 is a first-in-class, novel, next-generation
engineered peptide that empowers the immune system in vivo. The
Company’s technology primes the innate immune system to modulate
adaptive immunity thereby generating and expanding antigen-specific
cytotoxic T-cells in vivo. The company is advancing PIN-2 to the clinic
early first quarter 2017.

For more information about PIN Pharma and PIN-2, contact Mark Smith, CBO
(msmith@pinpharma.com) or
Colin Bier, CEO (cbier@pinpharma.com)
at PIN Pharma, Inc., 3960 Broadway, Suite 620, New York, NY, or call
212-543-2583.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005128/en/